Literature DB >> 27434598

The Role of Posttraumatic Growth in a Randomized Controlled Trial of Cognitive-Behavioral Conjoint Therapy for PTSD.

Anne C Wagner1, Lindsey Torbit1, Tiffany Jenzer2, Meredith S H Landy1, Nicole D Pukay-Martin3, Alexandra Macdonald4, Steffany J Fredman5, Candice M Monson1.   

Abstract

Posttraumatic growth (PTG) is defined as a positive psychological change that can emerge following a traumatic life event. Although documented in noninterventional studies of traumatized individuals, there are scant data on the potential for therapy to induce or improve PTG. Thus, the primary goal of this study was to examine changes in PTG in a controlled trial of cognitive-behavioral conjoint therapy for posttraumatic stress disorder versus waitlist (CBCT for PTSD; Monson & Fredman, 2012). We also examined whether pretreatment relationship satisfaction and PTSD symptomatology moderated change in PTG. There were 40 couples (75% with a female partner with PTSD) who were randomized to either immediate CBCT for PTSD or a 3-month waitlist (WL). Compared to WL, individuals who received treatment immediately demonstrated a significant increase in PTG. There was a moderate effect size between-group difference (Hedge's g = 0.45). There was a nonsignificant relationship with a moderate effect size (Hedge's g = 0.65) for the positive effect of pretreatment relationship satisfaction on the trajectory of PTG, but no effect of pretreatment PTSD symptoms. Results suggested that CBCT for PTSD facilitated PTG, even with a limited focus on PTG in this conjoint intervention. Future research should target PTG as a treatment goal and further examine the role of close others in facilitating development of PTG.
Copyright © 2016 International Society for Traumatic Stress Studies.

Entities:  

Mesh:

Year:  2016        PMID: 27434598      PMCID: PMC4988872          DOI: 10.1002/jts.22122

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN: 0894-9867


  7 in total

Review 1.  Positive change following trauma and adversity: a review.

Authors:  P Alex Linley; Stephen Joseph
Journal:  J Trauma Stress       Date:  2004-02

2.  Shared and unique predictors of post-traumatic growth and distress.

Authors:  Sharon Dekel; Christine Mandl; Zahava Solomon
Journal:  J Clin Psychol       Date:  2010-11-23

Review 3.  The development of a Clinician-Administered PTSD Scale.

Authors:  D D Blake; F W Weathers; L M Nagy; D G Kaloupek; F D Gusman; D S Charney; T M Keane
Journal:  J Trauma Stress       Date:  1995-01

4.  Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial.

Authors:  Candice M Monson; Steffany J Fredman; Alexandra Macdonald; Nicole D Pukay-Martin; Patricia A Resick; Paula P Schnurr
Journal:  JAMA       Date:  2012-08-15       Impact factor: 56.272

5.  Post-traumatic growth as outcome of a cognitive-behavioural therapy trial for motor vehicle accident survivors with PTSD.

Authors:  Tanja Zoellner; Sirko Rabe; Anke Karl; Andreas Maercker
Journal:  Psychol Psychother       Date:  2011-04-13       Impact factor: 3.915

6.  The Posttraumatic Growth Inventory: measuring the positive legacy of trauma.

Authors:  R G Tedeschi; L G Calhoun
Journal:  J Trauma Stress       Date:  1996-07

Review 7.  Post-traumatic growth in people living with a serious medical condition and its relations to physical and mental health: a systematic review.

Authors:  Tatjana Barskova; Rainer Oesterreich
Journal:  Disabil Rehabil       Date:  2009       Impact factor: 3.033

  7 in total
  2 in total

1.  The Traumatic Experience of Clinical Nurses During the COVID-19 Pandemic: Which Factors are Related to Post-Traumatic Growth?

Authors:  Xin Tong Zhang; Song Song Shi; Yu Qin Ren; Li Wang
Journal:  Risk Manag Healthc Policy       Date:  2021-05-24

2.  Eye Movement Desensitization and Reprocessing to Facilitate Posttraumatic Growth: A Prospective Clinical Pilot Study on Ferry Disaster Survivors.

Authors:  Sang Won Jeon; Changsu Han; Joonho Choi; Young-Hoon Ko; Ho-Kyoung Yoon; Yong-Ku Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-11-30       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.